Vice chair:



Jan Molenaar (The Netherlands), Louis Chessler (UK), Matthias Fischer (Germany), Anette Kunkele (Germany), Pablo Berlanga (France).


  • Be recognised as conduit for NBL NDD in Europe
  • Organise membership of NDD
  • Formalise links with COG/NANT (and others)
  • Drive preclinical NBL testing in Europe
  • Deliver on set up of X number of new trials
  • Influence front-line strategy
  • Work with the relapsed NB strategy working group to set up and deliver first relapse trial(s) in SIOPEN
  • Develop links with industry, particularly small biotechs interested in childhood cancers, as well as regulators